Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scinai Immunotherapeutics Ltd ADR (NQ: SCNI )

0.4598 +0.0098 (+2.18%)
Streaming Delayed Price Updated: 1:51 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Scinai Immunotherapeutics Ltd ADR

< Previous 1 2 Next >
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases FY 2023 Financial Results, Provides Business Update
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Nasdaq Delisting Notification and Appeal, ADS Ratio Change
Via Investor Brand Network
Vitamin D Could Balance Gut Microbiota, Boost Cancer Immunotherapy
Via Investor Brand Network
Potential Complications of Untreated Psoriasis
Via Investor Brand Network
Study Finds Presurgery Immunotherapy Safe for Patients with Pancreatic Cancer
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Chief Science Officer to Present at This Month’s Europe Dermatology Drug Development Summit
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), Scinai Bioservices Enter MSA with Ayana Pharma
Via Investor Brand Network
Gene Signature Could Predict NSC Lung Cancer Response to Immunotherapy
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Showcasing Services, Meeting with Investors at Upcoming BIO-Europe Spring 2024
Via Investor Brand Network
Siteman Cancer Center Starts Offering Novel Cell-Based Immunotherapy Against Melanoma
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Liat Halpert as Head of Business Development, Sales
Via Investor Brand Network
The Right to Health During Humanitarian Crises Should Include Noncommunicable Diseases
Via Investor Brand Network
Scientists Uncover Vital T-Cells in Kids’ Brains That Could Fight Brain Cancers
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Scientific Research Collaborator Receives Prestigious Louis-Jeantet Prize
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Releases Shareholder Letter
Via Investor Brand Network
Shining Spotlight on How Vitiligo Could Be Connected to Other Autoimmune Disorders
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Agreement for Million-Dollar Exercise of Outstanding Warrants
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces January Analyst, Investor Webinar
Via Investor Brand Network
New Research Redefines Pathophysiology of Rheumatoid Arthritis, Paves Way for Precision Treatments
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports on Preclinical Results from Psoriatic Human Skin Trial
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announced Peer-Reviewed Journal Publishes Data Supporting NanoAbs
Via Investor Brand Network
Exposures COVID-19
Many Fellowship Programs for Infectious Disease Specialists Remain Unfilled in US
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Maturity Extension of EIB Finance Facility
Via Investor Brand Network
Autoimmunity Patients Face Cost, Diagnosis, Care Challenges
Via Investor Brand Network
New, Deadly Infectious Diseases Could Emerge as Climate Change Worsens
Via Investor Brand Network
Topics Climate Change
Exposures Climate
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receive $900K IIA Grant for New CDMO Business Unit
Via Investor Brand Network
Topics Economy
Exposures Economy
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Status Report on NASDAQ Compliance
Via Investor Brand Network
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
From Scinai Immunotherapeutics Ltd.
Via GlobeNewswire
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
From Scinai Immunotherapeutics Ltd.
Via GlobeNewswire
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q3 2023 Financial Report, Reports Possible Adjustment of Facility Terms by EIB
Via Investor Brand Network
Exposures COVID-19
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.